Peptide basics
Semaglutide has five times the trial record of dulaglutide
On this page
Both compounds are approved and both have reached phase 4, the stage that only approved products can reach.
Semaglutide has 589 verified registered trials; dulaglutide has 115.
Enrolment across those trials is 199,228 for semaglutide and 52,264 for dulaglutide.
More evidence means more precisely characterised, not better. This page compares how much is known, not which one is preferable.
This page compares the evidence record of two compounds — how many trials, how far they reached, how many people took part. It is not a comparison of effectiveness or safety, does not recommend either, and contains no dose, schedule or route.
What each record contains
Semaglutide has 589 registered trials that we verified as administering it, enrolling 199,228 people in total. Dulaglutide has 115 such trials, enrolling 52,264. Both compounds have reached phase 4 and both have FDA-approved products.123
So the two are in the same regulatory position and a very different evidential one. Dulaglutide's record would be substantial for almost any compound on this site; it looks small only next to semaglutide's.12
Why the gap exists
Semaglutide was developed for two markets rather than one. It carries approvals in both diabetes and weight management, in injectable and oral presentations, and each of those required its own programme. Dulaglutide's approved use is narrower, and a narrower approved use generates fewer trials.3
Attention follows the same shape. Semaglutide's English Wikipedia article draws 54,466 views a month; dulaglutide's draws 2,756. That is a ratio of about nineteen to one, far wider than the ratio in the trial record.124
What a bigger record actually buys
It buys precision and coverage. More trials mean narrower confidence intervals, more populations studied, more comparisons against other treatments, and more chance that an uncommon harm has been observed.1
It also means more opportunity for inconsistent findings to surface, which is a feature. A compound with one trial cannot contradict itself.12
Common questions
Does more evidence mean semaglutide works better?
It does not follow. Head-to-head trials are the only thing that answers that, and the volume of separate trials for each compound says nothing about how they compare directly.
Why does the participant ratio differ from the trial ratio?
Because trials vary enormously in size. A record can be dominated by a few very large studies, which is why both counts are worth looking at.
Are these counts the same as what the registry search returns?
No. They are the verified subset. Raw registry searches return substantially more, including studies that never administered the compound.
Sources
- RegulatoryClinicalTrials.gov search — intervention: semaglutideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=semaglutide ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: dulaglutideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=dulaglutide ↗↩ Back to text
- RegulatoryDrugs@FDA — approved products containing semaglutide and dulaglutideU.S. Food and Drug Administration, 2026www.accessdata.fda.gov/scripts/cder/daf/ ↗↩ Back to text
- Secondary sourceWikimedia REST API — English Wikipedia pageviewsWikimedia Foundation, 2026wikimedia.org/api/rest_v1/#/Pageviews%20data ↗↩ Back to text